A non-invasive glucose sensor could be set to land in 2024.
Afon, a UK-based company, has created an RF sensor to track glucose levels in the blood. It claims that its sensor will track blood glucose tracking in real-time with no time lag.
The company tweeted: “Imagine having a device automatically alerting you when your blood sugar levels are going high or low and all that without taking a single drop of blood. Watch this space.”
And follow it up by claiming:
“Realistically we will be looking to have the device on the market in early 2024.”
The Afon Blood Glucose Sensor device is an external secondary sensor that fits under the base of the wrist.
The company says it uses RF technology, rather than the optical sensors found on current smartwatches, which uses radio frequencies to obtain signals from under the skin, rather than light.
If that sounds familiar to Wareable readers, it’s the same technology being trialed by Movano. We spoke to the Movano CEO recently, who explained that the company was starting trials on blood pressure tracking, before moving to blood glucose later this year.
Back to Afon, there are no details on how well the company is progressing with regulatory sign-off.
Commercializing the device in 2024 seems incredibly optimistic, given the level of accuracy needed to get past health regulators.
On the Afon website, the company explains:
“The Afon Blood Glucose Sensor has undergone three rounds of testing at Profil, the world-renowned diabetes research centre in Germany. Over the next year, we will undertake a multi-phase trial of our disruptive technology at the Joint Clinical Research Facility (JCRF) at Swansea University. Other multi-site trials are also planned in 2023 ahead of commercializing our device in 2024.”
But regulation isn’t mentioned. We’re reaching out to the company to get more details on what’s ahead. But should it get the product to market in 2024, it would be a huge leap forward, and the company will have outfoxed huge tech companies, in delivering something incredible for
How we test